Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

EOFlow

Explore full profile

Advanced and user friendly wearable drug delivery solutions

Seoul, South KoreaFounded 2011Health Tech & Medtech
Valuation $43M Market cap · 2026
Revenue $3.1M Latest reported FY

About EOFlow

EOFlow Co., Ltd., established in 2011 by Jesse J. Kim, is a company dedicated to developing wearable drug delivery systems. Kim's professional background includes time at the multidisciplinary design and consulting firm IDEO and later founding Insulet Corporation, which developed the first commercially successful tubeless insulin pump, OmniPod. This experience in both design and medical device development directly informs EOFlow's strategic direction. The company's headquarters are located in Seongnam, South Korea.

The company's flagship product is the 'EOPatch', a disposable and wearable insulin pump designed for individuals with diabetes. Functioning as a continuous subcutaneous insulin infusion (CSII) device, the EOPatch is tubeless and can be worn for up to 3.5 days. This design aims to offer greater freedom and convenience compared to traditional insulin pumps with tubing. The device is managed through the 'Narsha' smartphone application, which allows users to monitor their insulin delivery and glucose levels. The application is available on both Android and iOS platforms. Another key component of their system is the 'EOPump', a compact, disposable insulin reservoir with an integrated infusion set, which underpins the functionality of the EOPatch.

EOFlow operates in the competitive diabetes care market, specifically targeting the segment of insulin-dependent patients who require precise and continuous insulin management. Its business model centers on the sale of these disposable medical devices. The company has achieved several key milestones, including obtaining Korea's Ministry of Food and Drug Safety (MFDS) approval for the EOPatch in 2021. Following this, EOFlow secured a CE mark in Europe, also in 2021, paving the way for commercialization in that region. The company has also pursued entry into the U.S. market, submitting a 510(k) premarket notification to the FDA. In 2023, global medical technology firm Medtronic announced its intention to acquire EOFlow, signaling a significant valuation of the company's technology and market position.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2011
Headquarters
Seoul, South Korea
Listing
IPO 2020
Open positions
None listed
Dealroom signal
26.3/100
Industry
Health, Wellness Beauty
Sub-industry
Medical Devices
Sector
Health Tech & Medtech, Spinout, Wearable, DT and LS, science-based
Technology
Hardware, Deep Tech, Connected Device, IoT InternetOfThings
Business model
Manufacturing
Client focus
b2b

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITY✓Other financing Jul 2026 $22M — IPV ↗
ACQUISITION✓Exit May 2023 $738M $738M Medtronic ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMarginProfitMarginR&D
2026 $3.1M 0% −$16M -532.7% −$35M -1152.8% $1.8M
2025 $3.1M -27.1% −$16M -532.7% −$35M -1152.8% $1.8M
2024 $4.2M -23.6% −$46M -1090.9% −$53M -1244.7% $4.2M
2023 $5.5M -1.8% −$35M -642.5% $6.9M
2022 $5.6M +868% −$27M -484.5%
2021 $581K +3050% −$21M -3633.3%
2020 $18K — −$9.9M -53750.4%
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

EOFlow website traffic

Latest recorded traffic for EOFlow is 7.4K monthly website visits, down 1.3% over the last three months.

Latest monthly visits7.4K 3-month web change-1.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • LB Investment

Series B and later1 investor entered at this stage

  • IPV

Other known investors4 additional known investors

  • ActnerLab
  • Medtronic
  • Seoul National University
  • UTC Investment
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇰🇷 South Korea · Seoul HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about EOFlow on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See EOFlow’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.